

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/07533 A2

- (51) International Patent Classification⁷: **A23L**
- (21) International Application Number: **PCT/EP01/08283**
- (22) International Filing Date: **17 July 2001 (17.07.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
00115850.0 **24 July 2000 (24.07.2000)** **EP**
- (71) Applicant (for all designated States except US): **SOCIETE DES PRODUITS NESTLE S.A. [CH/CH]; P.O. Box 353, CH-1800 Vevey (CH).**
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ROCHAT, Florence [CH/CH]; Quartier des Tilleuls 6, CH-1820 Montreux (CH). BALLEVRE, Olivier [FR/CH]; 16B, route de Cojonnex, CH-1000 Lausanne 25 (CH). JANN, Alfred [CH/FR]; 255, rte de Pays de Gavot, F-74500 Publier (FR).**
- (74) Agent: **VUILLE, Roman; 55, avenue Nestlé, CH-1800 Vevey (CH).**
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**


Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,**

[Continued on next page]

(54) Title: **NUTRITIONAL COMPOSITION**

Effect of various CHO or blend on fecal bifidobacteria in man



(57) Abstract: A nutritional composition is disclosed which comprises synergistic functional carbohydrates for prevention or treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health. The carbohydrates have a synergistic activity on promoting bifidobacteria in the intestine. Also disclosed are a method of production of the composition; use of the composition in the manufacture of a functional food or medicament for the prevention or treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health; and a method of treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health which comprises administering an effective amount of the composition.



ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Nutritional Composition

The present invention relates to a nutritional composition which comprises synergistic functional carbohydrates for prevention or treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health; a method of production of the composition; use of the composition in the manufacture of a functional food or medicament for the prevention or treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health; and a method of treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health which comprises administering an effective amount of the composition.

Within the context of this specification the word "comprises" is taken to mean "includes, among other things". It is not intended to be construed as "consists of only".

Within the context of this specification the expression "side effects" is taken to mean unwished side effects often occurring after consumption of fiber. These side effects include, for example, flatulences, bloating and intestinal pain.

It has been suggested that there are health benefits associated with growth of bifidobacteria populations in the gut. These benefits include increased defence against pathogenic bacteria, stimulation of the immune system, and health benefits relating to the production of short chain fatty acids (SCFAs), as well as less abdominal sensation. All of these influence gut flora balance and gut health.

It is well known that infection by pathogenic bacteria can be detrimental to health. Examples of these bacteria include *Clostridium perfringens*, *C. difficile*, *Salmonella* and other enteropathogens.

In the past, infection by these harmful bacteria has been allowed to proceed until it must be treated by antibiotics. The antibiotics have a good effect on harmful bacteria. However, they suffer from the problem that they also kill populations of intestinal bacteria that are not harmful and that aid digestion of food. These bacterial populations are often referred to as "friendly".

Therefore, a need exists for a composition that is capable of preventing or combating infection by pathogenic bacteria, increasing defence against pathogenic bacteria, stimulating the immune system, and/or increasing short chain fatty acid production, all of which lead to promotion of gut flora balance and health.

The present invention addresses the problems set out above.

Remarkably, it has now been found that specific functional carbohydrates are capable of having a synergistic effect on the growth of bifidobacteria populations *in vitro* and *in vivo* in the gut.

Consequently, in a first aspect the present invention provides a nutritional composition for prevention or treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health which comprises at least two synergistic functional carbohydrates wherein a first carbohydrate is selected from the group which consists of inulin or fructooligosaccharide (FOS), and a second carbohydrate is selected from the group which consists of xylooligosaccharide (XOS), acacia gum and resistant starch. The carbohydrates may be obtained commercially or more simply by the use of a natural source (eg: chicory as source of inulin).

In a second aspect the invention provides a method of production of the composition which comprises blending the components in the required amounts.

In a third aspect the invention provides use of a composition according to an embodiment of the invention in the manufacture of a functional food or medicament for the prevention or treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health

In a fourth aspect, the invention provides the use of a composition according to an embodiment of the invention for the manufacture of a functional food or medicament comprising fiber but preventing side effects of the consumption of fiber.

In a fifth aspect, the invention provides the use of a composition according to an embodiment of the invention for manufacture of a functional food or medicament for the prevention or treatment of Irritable Bowel Syndrome (IBS).

5 In a sixth aspect the invention provides a method of treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health which comprises administering an effective amount of the composition according to an embodiment of the invention.

10 In a further aspect, the invention provides a method to reduce side effects of the consumption of fiber, which comprises administering fiber in form of the composition according to the invention.

In still an additional aspect, the present invention provides a method to reduce
15 the symptoms of the Irritable Bowel Syndrome (IBS), which comprises administering an effective amount of the composition according to the invention.

Preferably, an embodiment of a composition according to the present invention comprises fructooligosaccharide and a carbohydrate selected from the group
20 which consists of xylooligosaccharide and acacia gum. More preferably it comprises fructooligosaccharide and acacia gum.

Preferably, an embodiment of a composition according to the present invention comprises about 1g to about 20g of a first carbohydrate and about 0.1 to about
25 20g of a second carbohydrate. More preferably, it comprises about 1g to about 3g of a first carbohydrate and about 0.2g to about 3g of a second carbohydrate for infant. Most preferably, it comprises about 2g to about 5g of a first carbohydrate and about 2g to about 5g of a second carbohydrate for adult. Although it will be
30 apparent that there are no specific limitations except for what can reasonably be consumed and the price. These amounts given correspond to a daily dose, which may be divided into several servings in one day.

Preferably, in an embodiment of the composition a ratio by weight of the first and the second functional carbohydrate is 1 - 20 : 0.1 - 20. More preferably, it is
35 between 0.05 - 10 : 1, even more preferably, between 0.1 - 10 : 1.

Preferably, an embodiment of the composition is formulated for human consumption and/or administration. Preferably, an alternative embodiment is formulated for consumption by a companion animal.

5/ An advantage of the present invention is that it provides a composition that can be provided in a functional food product and which therefore does not require special administration.

10 Another advantage of the present invention is that it , but it does not adversely affect non-harmful intestinal bacteria or kill friendly bacteria present in the intestine.

15 Yet another advantage of the present invention is that it provides a decrease the daily amount of carbohydrates required in the gut to obtain stimulation of intestinal bifidobacteria and for promotion of the associated health benefit. The advantages that this decrease provides include reduction of the side effects (abdominal disturbance) induced by the intake of some fermentable carbohydrates, and in some cases a reduction in cost.

20 Yet another advantage of the present invention is that it provides a composition of carbohydrates having various lengths of carbohydrate chains. This provides the advantage of modulating fermentation throughout the colon as the composition passes through it.

25 Additional features and advantages of the present invention are described in, and will be apparent from, the description of the presently preferred embodiments which are set out below with reference to the drawings in which:

30 Figure 1 shows the effect of various carbohydrates or blends thereof on faecal bifidobacteria in man.

35 According to the invention it is possible to stimulate specifically the growth of intestinal bifidobacteria or other lactic acid bacteria by the use of specific non-digestible carbohydrates (fibre or fibre-like substances), in vivo and in vitro. In humans and animals the bifidobacteria population is not the same from one individual to another and often comprises several different species of bifidobacteria.

The bifidobacteria enzymes implicated in fermentation of embodiments of a composition according to the invention are not the identical and differ depending on the physical and chemical structures of the carbohydrates. In addition, the bifidobacteria are not similar with regard to their enzymatic capacity, and thus, the ability to ferment one or another fibre is not the same from one bacteria to another.

Thus, a composition according to the invention which comprises a mixture of two or more carbohydrates promotes the growth of more bifidobacteria species than a single carbohydrate. Surprisingly, a synergy exists between carbohydrates on the stimulation of bifidobacteria and their health benefits (examples of carbohydrates include: fructo-oligosaccharides, galacto-oligosaccharide, soybean-gum, gum, starch.

Additional features of compositions according to the invention are given below. Comparative data showing results in human studies of using Fructo-oligosaccharides plus Acacia Gum or plus Xylo-oligosaccharides are given in the Examples. The data demonstrate an higher increase of bifidobacteria with a synergistic mix of carbohydrates than with single carbohydrate. These examples are described below.

In an embodiment, a nutritional composition preferably comprises a source of protein. Dietary protein is preferred as a source of protein. The dietary protein may be any suitable dietary protein; for example animal protein (such as milk protein, meat protein or egg protein); vegetable protein (such as soy protein, wheat protein, rice protein, and pea protein); a mixture of free amino acids; or a combination thereof. Milk proteins such as casein, whey proteins and soy proteins are particularly preferred.

The composition may also comprise a source of carbohydrates and/or a source of fat.

If the nutritional formula includes a fat source, the fat source preferably provides about 5% to about 55% of the energy of the nutritional formula; for example about 20% to about 50% of the energy. Lipid making up the fat source may be any suitable fat or fat mixture. Vegetable fat is particularly suitable; for example

soy oil, palm oil, coconut oil, safflower oil, sunflower oil, corn oil, canola oil, lecithins, and the like. Animal fat such as milk fat may also be added if desired.

5 / An additional source of carbohydrate may be added to the nutritional composition. It preferably provides about 40% to about 80% of the energy of the nutritional composition. Any suitable carbohydrate may be used, for example sucrose, lactose, glucose, fructose, corn syrup solids, maltodextrin, or a mixture thereof.

10 Additional dietary fibre may also be added if desired. If added, it preferably comprises up to about 5% of the energy of the nutritional composition. The dietary fibre may be from any suitable origin, including for example soy, pea, oat, pectin, guar gum, gum arabic, fructooligosaccharide or a mixture thereof.

15 Suitable vitamins and minerals may be included in the nutritional composition in an amount to meet the appropriate guidelines.

20 One or more food grade emulsifiers may be included in the nutritional composition if desired; for example diacetyl tartaric acid esters of mono- and diglycerides, lecithin and mono- or di-glycerides or a mixture thereof. Similarly suitable salts and/or stabilisers may be included.

25 The nutritional composition is preferably enterally administrable; for example in the form of a powder, a liquid concentrate, or a ready-to-drink beverage. If it is desired to produce a powdered nutritional formula, the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.

30 Alternatively, a common food product may be enriched with an embodiment of the composition. For example, a fermented milk, a yoghurt, a fresh cheese, a renneted milk, a confectionery bar, breakfast cereal flakes or bars, a drink, milk powder, soy-based product, non-milk fermented product or a nutritional supplement for clinical nutrition, infant formulae or baby food. Then, the amount of the composition added is preferably at least about 0.01% by weight.

35 An embodiment of the composition may be included in an article of confectionery, for example a sweet or sweetened beverage.

The following examples are given by way of illustration only and in no way should be construed as limiting the subject matter of the present application. Percentages and parts are by weight unless otherwise indicated.

5 **Example 1: Nutritional Composition.**

A parallel design, consisting of 3 groups of 29 volunteers each, has been used:

FOS: 6g daily of (Raftilose P95N) during 6 weeks.

XOS: 0.4g daily of Xylo-oligo P95 during 6 weeks

10 **XOS FOS:** 4g daily of FOS and 0.2g daily of XOS, during 6 weeks

Before the 6 weeks of treatment, a wash-out period of 3 weeks was observed.

The participants were then followed-up during 5 additional weeks after the end of treatment. During the wash-out and follow-up periods, the volunteers received a
15 placebo.

During the complete test period, subjects refrained from eating fermented yoghurts and products containing bifidus.

20 In general the test subjects showed an increase of bifidobacteria counts, particularly those who had a low initial value. The average and median increases were also calculated. A formal statistical analysis gave the following results:

FOS [log ₁₀ cfu/g]	<i>Start</i>	<i>+1 Week</i>	<i>Diffe rence</i>	<i>p- value</i>
<i>Mean (t-test)</i>	8.41	9.02	+0.61	0.019

XOS [log ₁₀ cfu/g]				
<i>Mean (t-test)</i>	7.43	8.11	+0.68	0.042

XOS FOS [log ₁₀ cfu/g]				
<i>Mean (t-test)</i>	7.39	8.85	+1.45	<0.001

Differences of bifidobacteria counts between start and first week of treatment

The results shown in the table provide clear evidence that FOS and XOS FOS significantly increase the average bifidobacteria counts. This is also the case for XOS, but to a lesser extent. The increase obtained with the mix XOS FOS is synergistically higher.

5

Example 2 :

The trial was designed, according to the protocol, to compare three groups of 32 resp. 31 subjects in parallel:

10

FOS:

200 ml of skimmed milk with Raftilose P95[®], 6g per serving.

Fibergum:

200 ml of skimmed milk with Fibergum AS IRX[®], 6g per serving.

15

FOS + Fibergum:

200 ml of skimmed milk with Raftilose P95[®] (3g per serving) and Fibergum TX[®] (3g per serving).

20

Faeces samples were tested 7, 21, 28, 49 and 71 days after the start of the study. The intervention period is between day 21 and 49. The change from day 21 to day 28 is of particular interest.

According to the protocol, a +1.35 log₁₀ cfu/g of faeces increase of Bifidobacteria after one week of treatment is expected for the FOS + Fibergum group.

25

The individual changes in the FOS + Fibergum group from day 21 to day 28 are summarised below:

	Min.	1st Qu.	Mean	3rd Qu.	Max.
30	-0.33	0.07	1.384	1.42	6.73

The differences were analysed in two ways, first from a quantitative point of view, then more from a qualitative point of view:

35

Use of a robust location estimator, for example the M-estimator using Turkey's *bisquare* function gave an "average" of 0.307 log₁₀ cfu/g of faeces, close to the median value. A 95%-confidence interval was calculated by bootstrapping 1000

times (this is why the M-estimator was preferred compared to the median in this case). This gave as limits 0.14 and 1.00, that is an interval which does not include the value 0, indicating that the increase was statistically significant.

- 5 The "responders" were determined: we chose as criteria an increase of at least $+0.5 \log_{10}$ cfu/g of faeces. This was observed for 13 out of 29 subjects, which represented 44.8% of the volunteers. A 95%-confidence interval for this proportion was from 27 to 64%. We could say that at least 27% of the subjects respond to the diet provided, and it could be as much as 64%.

10

Using both approaches, we obtained a significant result.

For the **Fibergum** group, we obtained the following differences:

15	Min.	1st Qu.	Mean	3rd Qu.	Max.
	-6.26	0	0.6678	0.875	6.6

Here, median and mean differences were closer, and a *t*-test was appropriate. The average increase was at the limit of statistical significance (p -value = 0.09, 95%-CI: [-0.11, 1.45]).

20

Finally, for the **FOS** group, the differences were distributed as follows:

25	Min.	1st Qu.	Mean	3rd Qu.	Max.
	-4.04	0.0625	0.2853	0.655	4.31

Example 3 :

- 30 100 volunteers were assigned randomly to 4 diet groups, but stratified for their amount of native intestinal Bifidobacteria before the trial, sex, age and average portions of fiber in the daily diet. The 4 diet groups are described below:

- **Control**
Reference Product
- 35 • **FOS+GUM**
Raftilose® 3g and Fibergum 3.56g per serving
- **Starch**
Resistant Starch 10g per serving

- **Blend**

Raftilose® 3g + Fibergum 3.56g + Resistant Starch 10g per serving

5 The primary analysis was to outcome is the effect on the amount of Bifidobacteria in the faeces. Counts of other micro-organisms were also analysed. A further analysis was carried out to determine changes of abdominal sensation (flatulencies, quality and number of stools) as assessed by the volunteers, followed by analysis of several short chain fatty acids measured in the faeces.

10

The 100 volunteers were allocated to 4 groups as follows:

- Control: 13 subjects (8 females, 5 males)
- FOS+GUM: 29 subjects (19 females, 10 males)
- 15 • Starch: 29 subjects (19 females, 10 males)
- Blend: 29 subjects (19 females, 10 males)

20 Their average amount of bifidobacteria, age and portions of fiber were similar. There was one subject which clearly was not compliant (Group "FOS+GUM"), and its data were omitted.

25 It was set out to demonstrate that after 4 weeks of treatment, 50% of the subjects show an increase of at least +0.5 log₁₀ cfu/g of faeces of Bifidobacteria. The lower boundaries of a 95%-Confidence Interval (CI) for the estimated proportion should be above 25%.

30 For the duration "Day 20 to Day 48", the following results were obtained of log 10 cfu bifidobacteria/g faeces (p) in (n) number of people. The number out of (n) having at least 0.5 log₁₀ cfu/g is shown in the first column (+0.5).

30

Bifidobacteria: Day 48 minus day 20

	+0.5	n	p	Lower	Upper
35 Control	3	13	23.1	6.2	54.0
FOS+GUM	9	27	33.3	17.2	54.0
Starch	7	27	25.9	11.9	46.6
Blend	13	27	48.1	29.2	67.6

40 In the above table, we see that, in the *Control* group, there were 3 out of 13 subjects that have an increase of at least 0.5 log₁₀ cfu/g of faeces. This represents 23.1%, with a 95%-confidence interval (CI) ranging from 6.2% up to 54.0%. For the Blend, the proportion was close to 50%, and the lower boundary of the 95%-CI is above 25%. Clearly there was a significant effect after 4w of consuming the blend.

45

After 1 week, the following results were obtained:

Bifidobacteria: Day 27 minus day 20

		+0.5	n	p	Lower	Upper
5	Control	5	13	38.5	15.1	67.7
	FOS+GUM	12	28	42.9	25.0	62.6
	Starch	9	28	32.1	16.6	52.4
	Blend	11	29	37.9	21.3	57.6

10

Here, the effect of FOS+GUM was significant, and the blend was at the limit of statistical significance.

15

Changes in the amount of bifidobacteria were checked after 1 and 4 weeks of treatment to assess whether they related to the average portions of fiber eaten per subject. No striking association was found.

20

Similar experiments were carried out to determine the amounts of lactobacilli, bacteroides, enterobacteria and clostridium per fingens. It was surprisingly found that the number of these bacteria did not change significantly with respect to the different diets. This demonstrated the surprising result that an embodiment of the invention has the effect of specifically enhancing bifidobacteria. This result positively affects digestion, combats infection by pathogenic bacteria, stimulates the immune system, increases short chain fatty acid production and leads to promotion of gut flora balance and health.

25

30

It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is therefore intended that such changes and modifications be covered by the appended claims.


Claims

1. A nutritional composition for prevention or treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health which comprises at least two synergistic functional carbohydrates wherein a first carbohydrate is selected from the group which consists of inulin or fructooligosaccharide (FOS), and a second carbohydrate is selected from the group which consists of xylooligosaccharide (XOS), acacia gum and resistant starch.
2. A nutritional composition according to claim 1 which comprises chicory as a source of inulin.
3. A composition according to claim 1 or 2, which comprises fructooligosaccharide and a carbohydrate selected from the group which consists of xylooligosaccharide and acacia gum.
4. A composition according to claim 1 or 2, which comprises fructooligosaccharide and acacia gum.
5. A composition according to any preceding claim, wherein a ratio by weight of the first and the second functional carbohydrate is 1 - 20 : 0.1 - 20.
6. A composition according to any preceding claim which is formulated for human or companion animal consumption and/or administration.
7. A composition according to any preceding claim, which comprises a third carbohydrate, which is resistant starch.
8. A method of production of a composition according to any preceding claim, which comprises blending the components in the required amounts.
9. Use of a composition according to any one of claims 1 to 7 in the manufacture of a functional food or medicament for the prevention or treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health.

10. Use of a composition according to any one of claims 1 to 7 for the manufacture of a functional food or a medicament comprising fiber but preventing side effects of the consumption of fiber.
- 5 11. Use of a composition according to any one of claims 1 to 7 for manufacture of a functional food or medicament for the prevention or treatment of Irritable Bowel Syndrome (IBS).
- 10 12. A method of treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health, which comprises administering an effective amount of a composition according to any one of claims 1 to 7.
- 15 13. A method to reduce side effects of the consumption of fiber, which comprises administering fiber in form of the composition according to any one of claims 1 to 7.
- 20 14. A method to reduce the symptoms of the Irritable Bowel Syndrome (IBS), which comprises administering an effective amount of a composition according to any one of claims 1 to 7.

Figure 1

Effect of various CHO or blend on fecal bifidobacteria in man



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/07533 A3

(51) International Patent Classification⁷: A61K 31/70,
31/715, A23L 1/053, 1/0522, 1/308, 1/0528

(21) International Application Number: PCT/EP01/08283

(22) International Filing Date: 17 July 2001 (17.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00115850.0 24 July 2000 (24.07.2000) EP

(71) Applicant (for all designated States except US): SOCI-
ETE DES PRODUITS NESTLE S.A. [CH/CH]; P.O. Box
353, CH-1800 Vevey (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ROCHAT, Florence
[CH/CH]; Quartier des Tilleuls 6, CH-1820 Montreux
(CH). BALLEVRE, Olivier [FR/CH]; 16B, route de
Cojonnex, CH-1000 Lausanne 25 (CH). JANN, Alfred
[CH/FR]; 255, rte de Pays de Gavot, F-74500 Publier (FR).

(74) Agent: VUILLE, Roman; 55, avenue Nestlé, CH-1800
Vevey (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).


Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL,
SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ,

[Continued on next page]

(54) Title: NUTRITIONAL COMPOSITION

**Effect of various CHO or blend on fecal bifidobacteria in
man**



(57) Abstract: A nutritional composition is disclosed which comprises synergistic functional carbohydrates for prevention or treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health. The carbohydrates have a synergistic activity on promoting bifidobacteria in the intestine. Also disclosed are a method of production of the composition; use of the composition in the manufacture of a functional food or medicament for the prevention or treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health; and a method of treatment of infection by pathogenic bacteria and/or promoting gut flora balance and health which comprises administering an effective amount of the composition.



MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(88) Date of publication of the international search report:

11 April 2002

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 01/08283

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/70 A61K31/715 A23L1/053 A23L1/0522 A23L1/308
A23L1/0528

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23L A61K A23G

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ, FSTA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 444 054 A (GARLEB KEITH A ET AL) 22 August 1995 (1995-08-22) tables 6,13,14 claims 1,7,10,13 ---	1,3-14
X	EP 0 756 828 A (NUTRICIA NV) 5 February 1997 (1997-02-05) claims 1,4-6; example 1 column 3, line 31 - line 44 ---	1,6-14
A	US 5 721 004 A (JAMES SHERIANNE M) 24 February 1998 (1998-02-24) claims 1,4,5,9 column 3, line 66 -column 4, line 23 --- -/--	1,2,5,6, 8



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

7 February 2002

Date of mailing of the international search report

14/02/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Lepretre, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/08283

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 850 569 A (NESTLE SA) 1 July 1998 (1998-07-01) claims 1,5-8 page 3, line 17 - line 25 page 5, line 4 - line 7 page 7, line 31 - line 33; example 5 ---	1,2,6,8
A	GIBSON G R ET AL: "DIETARY MODULATION OF THE HUMAN COLONIC MICROBIOTA: INTRODUCING THE CONCEPT OF PREBIOTICS" JOURNAL OF NUTRITION, WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, PHILADELPHIA, PA., US, vol. 125, no. 6, June 1995 (1995-06), pages 1401-1412, XP000972244 ISSN: 0022-3166 page 1410, left-hand column -----	1-14

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 12-14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/EP 01/08283

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5444054	A	22-08-1995	AU 689555 B2	02-04-1998
			AU 1884495 A	23-10-1995
			CA 2187628 A1	12-10-1995
			EP 0754001 A1	22-01-1997
			NZ 281878 A	24-02-1997
			WO 9526646 A1	12-10-1995

EP 0756828	A	05-02-1997	EP 0756828 A1	05-02-1997
			AU 702989 B2	11-03-1999
			AU 6087196 A	06-02-1997
			DE 69506095 D1	24-12-1998
			DE 69506095 T2	24-06-1999
			ES 2123903 T3	16-01-1999
			US 5792754 A	11-08-1998

US 5721004	A	24-02-1998	CA 2198681 A1	01-09-1997

EP 0850569	A	01-07-1998	EP 0850569 A1	01-07-1998
			GR 3034480 T3	29-12-2000
			AT 194461 T	15-07-2000
			AU 728677 B2	18-01-2001
			AU 4853897 A	25-06-1998
			BR 9706448 A	23-11-1999
			CA 2221526 A1	24-06-1998
			DE 69702491 D1	17-08-2000
			DE 69702491 T2	19-04-2001
			DK 850569 T3	16-10-2000
			ES 2148900 T3	16-10-2000
			JP 10215805 A	18-08-1998
			NO 975915 A	25-06-1998
			NZ 329418 A	29-07-1999
			PT 850569 T	29-12-2000
			US 6197361 B1	06-03-2001
			US 5952033 A	14-09-1999
			ZA 9711529 A	22-06-1999
